NL-OMON36850已完成不适用
Excretion balance, pharmacokinetics and metabolism of S 38844 after single oral dose administration of [14C]-S 38844 in healthy male volunteers. - 14C-S 38844 ADME study
Institut de Recherches Internationales Servier I.R.I.S0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy Caucasian male volunteers, aged 18 - 64 years inclusive
- •18.5 * body mass index * 30.0 kg/m2
- •50 kg * body weight *100 kg
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating of participating in another ADME study in the 12 months prior the start of this study, with a radiation burden of >0,1 mSv.
研究者
相似试验
已完成
不适用
Excretion balance, pharmacokinetics and metabolism of S 47445 after single oral administration of 20mg [14C]-S 47445 in young healthy male volunteers.dementiaNL-OMON35510Institut de Recherches Internationales Servier I.R.I.S4
已完成
不适用
Excretion balance, pharmacokinetics and metabolism of S44819 after single administration of [14C]-S44819 in young healthy male volunteers. A phase 1 monocentre open-label study.strokeNL-OMON44446Institut de Recherches Internationales Servier (I.R.I.S.)4
终止
1 期
A Study in Healthy Men to Test How BI 1265162 is Taken up and Processed by the BodyHealthy VolunteersNCT04267276Boehringer Ingelheim7
已完成
不适用
Absorption, metabolism, excretion, and the determination of absolute bioavailability of Niraparib in subjects with cancercancerand that may benefit from treatment with a PARP inhibitormetastatic or locally advanced solid tumors that have failed to respond to standard therapyhave progressed despite standard therapyor for which no standard therapy existsrefuse standard therapy10027655NL-OMON41940TESARO, Inc12
已完成
1 期
Mass Balance, Pharmacokinetics and Metabolism Study of AlisertibAdvanced Solid TumorsLymphomaNCT01714947Millennium Pharmaceuticals, Inc.3